COVI-AMG

COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)

Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection.  STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments.

In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2 at concentrations of 78 ng/ml. The neutralization activity at this concentration protected against both the original SARS-CoV-2 virus isolate and the highly contagious Spike D614G isolate. 

A few highlights of the data from the most recent STI-2020 study include:

  • Hamsters infected with SARS-CoV-2 and then treated with a single dose of 500 µg STI-2020 started gaining weight within 48 hours of STI-2020 administration, as compared to control animals that steadily lost weight for 5 days before recovery.
  • At day 5, STI-2020-treated (500 µg) hamsters had gained 5% weight, versus a weight loss of about 10% for the control animals (15% difference).
  • At day 5, all STI-2020-treated (500 µg) hamsters (5 out of 5 analyzed animals) had undetectable virus load in lungs as compared to the lungs of animals in the control group, where more than 1,000 infectious viral particles per gram of tissue were readily detected.